Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Efficacy and Safety of CRMD-001 in Contrast-Induced Acute Oxidative Kidney Injury

NCT01146925 is registered in ClinicalTrials.gov with CorMedix Therapeutics as lead sponsor.

NCT NCT01146925
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01146925 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Efficacy and Safety of CRMD-001 in Contrast-Induced Acute Oxidative Kidney Injury
Lead sponsor
CorMedix Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2010
Completion date
June 30, 2011
Enrollment
60 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

contrast-induced acute kidney injury